Antisense, Immunomodulators Drive Progress In Huntington's Disease
Executive Summary
Impending clinical trial readouts will indicate whether pharmaceutical companies are on the right track to develop new investigational agents against the cause of the neurodegenerative disorder, Huntington's disease.
You may also be interested in...
Vaccinex Sees Mixed Signals In Huntington’s Study
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
Laquinimod Prospects Seen Small After RRMS CONCERTO Trial Failure
Teva has no current plans to further pursue laquinimod in relapsing-remitting multiple sclerosis after the investigational asset, developed by Sweden's Active Biotech, failed in the CONCERTO Phase III trial.
Teva’s Austedo Positioned To Compete With A Generic Rival
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.